NPPB and type 2 diabetes mellitus: Our results highlight the potential utility of incorporating NT-proBNP as a single biomarker to identify individuals with type 2 diabetes who are at risk of cardiorenal endpoints, and highlight its utility in patient stratification and potential prioritisation for use of organ-protective agents with cardiorenal benefits.